Literature DB >> 30201819

Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.

Lois W Martin1, Cynthia L Robson1, Annabelle M Watts1, Andrew R Gray2, Claire E Wainwright3,4, Scott C Bell4,5,6, Kay A Ramsay1,4,5, Timothy J Kidd5, David W Reid5,6, Ben Brockway7, Iain L Lamont8.   

Abstract

The lungs of individuals with cystic fibrosis (CF) become chronically infected with Pseudomonas aeruginosa that is difficult to eradicate by antibiotic treatment. Two key P. aeruginosa antibiotic resistance mechanisms are the AmpC β-lactamase that degrades β-lactam antibiotics and MexXYOprM, a three-protein efflux pump that expels aminoglycoside antibiotics from the bacterial cells. Levels of antibiotic resistance gene expression are likely to be a key factor in antibiotic resistance but have not been determined during infection. The aims of this research were to investigate the expression of the ampC and mexX genes during infection in patients with CF and in bacteria isolated from the same patients and grown under laboratory conditions. P. aeruginosa isolates from 36 CF patients were grown in laboratory culture and gene expression measured by reverse transcription-quantitative PCR (RT-qPCR). The expression of ampC varied over 20,000-fold and that of mexX over 2,000-fold between isolates. The median expression levels of both genes were increased by the presence of subinhibitory concentrations of antibiotics. To measure P. aeruginosa gene expression during infection, we carried out RT-qPCR using RNA extracted from fresh sputum samples obtained from 31 patients. The expression of ampC varied over 4,000-fold, while mexX expression varied over 100-fold, between patients. Despite these wide variations, median levels of expression of ampC in bacteria in sputum were similar to those in laboratory-grown bacteria. The expression of mexX was higher in sputum than in laboratory-grown bacteria. Overall, our data demonstrate that genes that contribute to antibiotic resistance can be highly expressed in patients, but there is extensive isolate-to-isolate and patient-to-patient variation.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; antibiotic resistance; beta-lactamase; cystic fibrosis; efflux pump; efflux pumps; gene expression

Mesh:

Substances:

Year:  2018        PMID: 30201819      PMCID: PMC6201108          DOI: 10.1128/AAC.01789-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  57 in total

1.  Genetic recombination in Pseudomonas aeruginosa.

Authors:  B W HOLLOWAY
Journal:  J Gen Microbiol       Date:  1955-12

Review 2.  Pseudomonas aeruginosa: all roads lead to resistance.

Authors:  Elena B M Breidenstein; César de la Fuente-Núñez; Robert E W Hancock
Journal:  Trends Microbiol       Date:  2011-06-12       Impact factor: 17.079

3.  Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.

Authors:  John Quale; Simona Bratu; Jyoti Gupta; David Landman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

4.  Effect of salt concentration on the apparent in-vitro susceptibility of Pseudomonas and other gram-negative bacilli to gentamicin.

Authors:  A A Medeiros; T F O'Brien; W E Wacker; N F Yulug
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

5.  Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa.

Authors:  N Masuda; E Sakagawa; S Ohya; N Gotoh; H Tsujimoto; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

6.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

7.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

Review 8.  Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms.

Authors:  Philip D Lister; Daniel J Wolter; Nancy D Hanson
Journal:  Clin Microbiol Rev       Date:  2009-10       Impact factor: 26.132

9.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

Review 10.  Pseudomonas aeruginosa Evolutionary Adaptation and Diversification in Cystic Fibrosis Chronic Lung Infections.

Authors:  Craig Winstanley; Siobhan O'Brien; Michael A Brockhurst
Journal:  Trends Microbiol       Date:  2016-03-03       Impact factor: 17.079

View more
  9 in total

1.  Express Yourself: Quantitative Real-Time PCR Assays for Rapid Chromosomal Antimicrobial Resistance Detection in Pseudomonas aeruginosa.

Authors:  Derek S Sarovich; Erin P Price; Danielle E Madden; Olusola Olagoke; Timothy Baird; Jane Neill; Kay A Ramsay; Tamieka A Fraser; Scott C Bell
Journal:  Antimicrob Agents Chemother       Date:  2022-04-25       Impact factor: 5.938

2.  Gene-Gene Interactions Dictate Ciprofloxacin Resistance in Pseudomonas aeruginosa and Facilitate Prediction of Resistance Phenotype from Genome Sequence Data.

Authors:  Attika Rehman; Julie Jeukens; Roger C Levesque; Iain L Lamont
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

3.  Diallyl sulfide from garlic suppresses quorum-sensing systems of Pseudomonas aeruginosa and enhances biosynthesis of three B vitamins through its thioether group.

Authors:  Wen-Ru Li; Tao-Hua Zeng; Jun-Wei Yao; Li-Ping Zhu; Zhi-Qing Zhang; Xiao-Bao Xie; Qing-Shan Shi
Journal:  Microb Biotechnol       Date:  2020-12-30       Impact factor: 5.813

4.  The Effects of Sub-inhibitory Antibiotic Concentrations on Pseudomonas aeruginosa: Reduced Susceptibility Due to Mutations.

Authors:  Kay A Ramsay; Sharla M McTavish; Samuel J T Wardell; Iain L Lamont
Journal:  Front Microbiol       Date:  2021-12-20       Impact factor: 5.640

5.  Genome evolution drives transcriptomic and phenotypic adaptation in Pseudomonas aeruginosa during 20 years of infection.

Authors:  Samuel J T Wardell; Jeff Gauthier; Lois W Martin; Marianne Potvin; Ben Brockway; Roger C Levesque; Iain L Lamont
Journal:  Microb Genom       Date:  2021-11

6.  Aminoglycoside-Modifying Enzymes Are Sufficient to Make Pseudomonas aeruginosa Clinically Resistant to Key Antibiotics.

Authors:  Aswin Thacharodi; Iain L Lamont
Journal:  Antibiotics (Basel)       Date:  2022-07-01

Review 7.  High-throughput sequencing technologies in the detection of livestock pathogens, diagnosis, and zoonotic surveillance.

Authors:  Godagama Gamaarachchige Dinesh Suminda; Srishti Bhandari; Yoonkyung Won; Umesh Goutam; Krishna Kanth Pulicherla; Young-Ok Son; Mrinmoy Ghosh
Journal:  Comput Struct Biotechnol J       Date:  2022-09-26       Impact factor: 6.155

8.  EGCG-Mediated Potential Inhibition of Biofilm Development and Quorum Sensing in Pseudomonas aeruginosa.

Authors:  Suqi Hao; Dan Yang; Ling Zhao; Fei Shi; Gang Ye; Hualin Fu; Juchun Lin; Hongrui Guo; Ran He; Jianlong Li; Hongwei Chen; Muhammad Faraz Khan; Yinglun Li; Huaqiao Tang
Journal:  Int J Mol Sci       Date:  2021-05-06       Impact factor: 5.923

9.  Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learning-enabled molecular diagnostics.

Authors:  Ariane Khaledi; Aaron Weimann; Monika Schniederjans; Ehsaneddin Asgari; Tzu-Hao Kuo; Antonio Oliver; Gabriel Cabot; Axel Kola; Petra Gastmeier; Michael Hogardt; Daniel Jonas; Mohammad Rk Mofrad; Andreas Bremges; Alice C McHardy; Susanne Häussler
Journal:  EMBO Mol Med       Date:  2020-02-12       Impact factor: 12.137

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.